UMOD and myeloid sarcoma: Given that MS is linked to an elevated risk of cardiovascular and kidney complications, and that CKD in MS can progress to end-stage kidney disease, our goal was to look at the possibilities of using uromodulin as a predictor of metabolic status in patients with CKD, independent of GFR.